Clinical Trial Update: Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT) [Phase 3]

View source ↗

Summary

A Phase 3 trial (REACT) evaluating clarithromycin to prevent progression to sepsis in community-acquired pneumonia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia

Drugs mentioned

• clarithromycin (clarithromycin)

Snippet

Sponsor: Hellenic Institute for the Study of Sepsis | Conditions: Community-acquired Pneumonia | Phase 3 | Status: RECRUITING